Car T Kymriah denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for car t kymriah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Not-FDA-Approved Denial for Kymriah

Kymriah (tisagenlecleucel) carries full FDA approval for certain hematologic malignancies. A "not-FDA-approved" denial from UnitedHealthcare almost always signals one of two things: (1) the specific indication listed in the claim does not precisely match the wording of an approved indication in the prescribing label, or (2) the therapy is being proposed for an off-label use that falls outside the approved labeling. Understanding which situation applies is the first step in crafting an effective appeal.

## Why This Denial Is Appealable

If the patient's diagnosis and intended use match an FDA-approved indication, this denial is factually incorrect and should be overturned on the administrative record alone. If the use is off-label, federal law and most state insurance codes still require coverage in certain circumstances — particularly when the off-label use is supported by recognized compendia (such as those referenced in Medicare policy) or by applicable professional guidelines. Either way, the denial is worth challenging.

## Federal Appeal Framework

• Internal appeal: Respond promptly to the Explanation of Benefits denial notice. Attach the FDA-approved prescribing label and clearly highlight the approved indication that covers your patient's case.
• Expedited review: Available if delay poses serious health risk; request it in writing.
• External Independent Review (ACA §2719): Escalate after internal exhaustion. An IRO must evaluate whether the denial was consistent with applicable clinical standards and FDA labeling.
• ERISA §503: Full-and-fair review applies to employer plans; approximately four months from denial to file for external review.

## Documentation to Gather

1. FDA prescribing label — obtain the current full prescribing information for Kymriah and annotate the exact approved indication that applies to your patient. 2. Diagnosis confirmation — pathology, cytogenetics, molecular, and staging documentation confirming the diagnosis maps precisely to the labeled indication. 3. Indication match letter — a letter from the treating oncologist/hematologist stating explicitly that the proposed use is on-label and explaining the clinical basis. 4. If off-label — citations from recognized drug compendia and the applicable professional society guideline (e.g., the applicable NCCN guideline) supporting the use. 5. Prior-treatment history — complete records establishing the patient's treatment course to date.

## Criteria-Mapping Structure

Side-by-side table: left column — each FDA-approved indication criterion from the prescribing label; right column — exact chart fact (date, pathology result, disease-relapse note) demonstrating the patient meets it. If UHC's denial letter cites a specific policy number or exclusion language, quote that language in the table and rebut each clause individually with clinical documentation. Precision in matching indication language eliminates the "not approved" argument at its root.